GlassScriptPhysician profile
Booth H Durham
NPI 1740392075
$33,707.38
in general payments reported to CMS, 2019-2025
53 companies · $4,253 in 2025
The $4,253 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,246 · 2020: $1,569 · 2021: $2,440 · 2022: $4,432 · 2023: $7,148 · 2024: $4,620 · 2025: $4,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $2,800 · Education: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,826.49 |
| Consulting Fee | $2,800.00 |
| Education | $393.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,866.55 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $4,208.54 | 2019-2025 | |
| Pfizer INC. | $3,288.07 | 2019-2025 | |
| Abbvie INC. | $2,735.88 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,827.79 | 2019-2025 | Siliq, Targretin, Cabtreo |
| Lilly USA, LLC | $1,779.66 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $1,715.93 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $1,534.73 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $1,454.58 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $1,391.54 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $1,145.76 | 2021-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $904.93 | 2023-2025 | Zoryve |
| Genzyme Corporation | $710.68 | 2019-2025 | |
| Almirall LLC | $659.20 | 2019-2025 | Seysara |
| Galderma Laboratories, L.P. | $618.50 | 2019-2025 | Aklief, Nemluvio, Epsolay |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Booth Durham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.